These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 2938738)

  • 1. Active specific immunotherapy of Dukes B2 and C colorectal carcinoma: comparison of two doses of the vaccine.
    Jessup JM; McBride CM; Ames FC; Guarda L; Ota DM; Romsdahl MM; Martin RG
    Cancer Immunol Immunother; 1986; 21(3):233-9. PubMed ID: 2938738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delayed cutaneous hypersensitivity to autologous tumor cells in colorectal cancer patients immunized with an autologous tumor cell: Bacillus Calmette-Guérin vaccine.
    Hoover HC; Surdyke M; Dangel RB; Peters LC; Hanna MG
    Cancer Res; 1984 Apr; 44(4):1671-6. PubMed ID: 6704973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed-type hypersensitivity reactions to tumor-associated antigens in colon carcinoma patients immunized with an autologous tumor cell/Bacillus Calmette-Guérin vaccine.
    Bloemena E; Gall H; Ransom JH; Pomato N; Murray JH; Bos E; Scheper RJ; Meijer CJ; Hanna MG; Vermorken JB
    Cancer Res; 1993 Feb; 53(3):456-9. PubMed ID: 7678773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.
    Berd D; Maguire HC; McCue P; Mastrangelo MJ
    J Clin Oncol; 1990 Nov; 8(11):1858-67. PubMed ID: 2230873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer.
    Habal N; Gupta RK; Bilchik AJ; Yee R; Leopoldo Z; Ye W; Elashoff RM; Morton DL
    Ann Surg Oncol; 2001 Jun; 8(5):389-401. PubMed ID: 11407512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide.
    Berd D; Mastrangelo MJ
    Cancer Invest; 1988; 6(3):337-49. PubMed ID: 3167614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific active immunotherapy in patients with adenocarcinoma of the colon utilizing tumor-associated antigens (TAA). A phase I clinical trial.
    Hollinshead A; Elias EG; Arlen M; Buda B; Mosley M; Scherrer J
    Cancer; 1985 Aug; 56(3):480-9. PubMed ID: 4005810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant immunotherapy and chemoimmunotherapy in colorectal cancer (Dukes' class C): prolongation of disease-free interval and survival.
    Mavligit GM; Gutterman JU; Malahy MA; Burgess MA; McBride CM; Jubert A; Hersh EM
    Cancer; 1977 Nov; 40(5 Suppl):2726-30. PubMed ID: 922710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma.
    Fenton RG; Steis RG; Madara K; Zea AH; Ochoa AC; Janik JE; Smith JW; Gause BL; Sharfman WH; Urba WJ; Hanna MG; DeJager RL; Coyne MX; Crouch RD; Gray P; Beveridge J; Creekmore SP; Holmlund J; Curti BD; Sznol M; Longo DL
    J Immunother Emphasis Tumor Immunol; 1996 Sep; 19(5):364-74. PubMed ID: 8941876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma.
    Dillman RO; Barth NM; VanderMolen LA; Garfield DH; De Leon C; O'Connor AA; Mahdavi K; Nayak SK
    Cancer Biother Radiopharm; 2001 Feb; 16(1):47-54. PubMed ID: 11279797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guèrin: five-year results of a prospective randomized study.
    Galligioni E; Quaia M; Merlo A; Carbone A; Spada A; Favaro D; Santarosa M; Sacco C; Talamini R
    Cancer; 1996 Jun; 77(12):2560-6. PubMed ID: 8640706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy of human solid tumors with Bacillus Calmette-Guérin: prolongation of disease-free interval and survival in malignant melanoma, breast, and colorectal cancer.
    Gutterman JU; Mavligit GM; Blumenshein G; Burgess MA; McBride CM; Hersh EM
    Ann N Y Acad Sci; 1976; 277(00):135-59. PubMed ID: 1069546
    [No Abstract]   [Full Text] [Related]  

  • 13. Irradiated cells from autologous tumor cell lines as patient-specific vaccine therapy in 125 patients with metastatic cancer: induction of delayed-type hypersensitivity to autologous tumor is associated with improved survival.
    Dillman RO; Beutel LD; Barth NM; de Leon C; O'Connor AA; DePriest C; Nayak SK
    Cancer Biother Radiopharm; 2002 Feb; 17(1):51-66. PubMed ID: 11915174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
    Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
    Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
    Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
    J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer.
    Hoover HC; Surdyke MG; Dangel RB; Peters LC; Hanna MG
    Cancer; 1985 Mar; 55(6):1236-43. PubMed ID: 3882219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgical adjuvant immunotherapy for colorectal cancer.
    Enker WE; Jacobitz JL; Craft K; Wissler RW
    J Surg Oncol; 1978; 10(5):389-97. PubMed ID: 732327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postoperative active specific immunization in curatively resected colorectal cancer patients with a virus-modified autologous tumor cell vaccine.
    Lehner B; Schlag P; Liebrich W; Schirrmacher V
    Cancer Immunol Immunother; 1990; 32(3):173-8. PubMed ID: 2289211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283.
    Harris JE; Ryan L; Hoover HC; Stuart RK; Oken MM; Benson AB; Mansour E; Haller DG; Manola J; Hanna MG
    J Clin Oncol; 2000 Jan; 18(1):148-57. PubMed ID: 10623705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of colon-tumor-associated antigens by T-cell lines derived from tumor-infiltrating lymphocytes and peripheral-blood lymphocytes from patients immunized with an autologous tumor-cell/bacillus Calmette-Guérin vaccine.
    Ransom JH; Pelle BA; Hubers H; Keynton LM; Hanna MG; Pomato N
    Int J Cancer; 1993 Jul; 54(5):734-40. PubMed ID: 8325703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.